In hemodialysis patients without acute heart attacks, elevated troponin T predicted heart failure events while elevated BNP (B-type natriuretic peptide) predicted both heart failure and vascular events — showing these biomarkers reflect different types of cardiac risk.
r = 0.531 (cTnT-BNP correlation)Troponin T and BNP were correlated but predicted different types of cardiovascular events in hemodialysis patients
What the researchers found
In 174 chronic hemodialysis patients without acute coronary syndrome, troponin T (cTnT) correlated strongly with BNP (r=0.531, p<0.001) and ANP (r=0.411, p<0.001). However, elevated cTnT was not associated with the presence or extent of coronary artery disease (CAD), unlike BNP and ANP which were.
All three biomarkers correlated independently with left ventricular end-diastolic pressure (LVEDP) and were associated with NYHA heart failure classification and peripheral artery disease. For prognosis, both cTnT and BNP predicted mortality and heart failure hospitalization, but only BNP predicted vascular events. This indicates cTnT elevation in dialysis patients reflects myocardial stress (heart failure) rather than atherosclerotic disease.
Why it matters
Dialysis patients have extremely high cardiovascular mortality, and their cardiac biomarkers are frequently elevated even without a heart attack, making clinical decisions difficult. This study clarifies that troponin T elevation in these patients signals heart failure pressure overload rather than blocked arteries — a critical distinction for treatment decisions. Meanwhile, the natriuretic peptides BNP and ANP provide broader cardiovascular risk information.
How the study worked
Prospective observational study of 174 consecutive chronic hemodialysis patients referred for coronary angiography for stable CAD, peripheral artery disease, or heart failure. Hemodynamic measurements, coronary angiography, and simultaneous blood sampling for cTnT, BNP, and ANP were performed. Prognostic potential for all-cause mortality, cardiac death/heart failure hospitalization, and vascular events was assessed.
What this study cannot tell us
This was a single-center observational study with a moderate sample size (174 patients). All patients were referred for coronary angiography, which may introduce referral bias. The study did not include serial biomarker measurements over time. The absence of high-sensitivity troponin assays (the newer standard) limits direct applicability to current practice. The results may not generalize to dialysis patients not referred for cardiac evaluation.
How to read the evidence
This is a single-center prospective observational study with a moderate sample size (174 patients) and hemodynamic data from cardiac catheterization. The study provides good quality observational evidence but is limited by its single-center design and specific referral population.
When this study was published
Published in 2019, this study addresses an ongoing clinical challenge in nephrology and cardiology. The interpretive framework for cardiac biomarkers in dialysis patients remains an active area of research.
The bigger picture
Natriuretic peptides (BNP, ANP) are peptide hormones released by the heart under stress — they're among the most important biomarkers in cardiology. This study demonstrates that in the complex setting of chronic kidney disease, different cardiac biomarkers carry distinct clinical meanings. As precision medicine advances, understanding which peptide biomarker best predicts which type of cardiovascular event is essential for tailoring treatment to individual patients.
Questions still open
- Would high-sensitivity troponin assays provide better discrimination between heart failure and coronary disease in dialysis patients?
- Could combining cTnT and BNP measurements improve risk stratification beyond either biomarker alone in this population?
- Do the prognostic differences between cTnT and BNP hold in peritoneal dialysis patients as well as hemodialysis patients?
Common questions
What are BNP and ANP and why are they elevated in dialysis patients?
Why is interpreting troponin so difficult in dialysis patients?
Read the original research
Clinical Significance of Increased Cardiac Troponin T in Patients with Chronic Hemodialysis and Cardiovascular Disease: Comparison to B-Type Natriuretic Peptide and A-Type Natriuretic Peptide Increase.
Kidney & blood pressure research, 44(5), 1050-1062
Citation
Niizuma, Shinichiro; Iwanaga, Yoshitaka; Washio, Takehiko; Ashida, Tadashi; Harasawa, Shinsuke; Miyazaki, Shunichi; Matsumoto, Naoya. (2019). Clinical Significance of Increased Cardiac Troponin T in Patients with Chronic Hemodialysis and Cardiovascular Disease: Comparison to B-Type Natriuretic Peptide and A-Type Natriuretic Peptide Increase.. Kidney & blood pressure research, 44(5), 1050-1062. https://doi.org/10.1159/000502232